The latest clinical trial protocol in Future Oncology describes the ongoing NeoADAURA study that is investigating neoadjuvant osimertinib with or without chemotherapy versus chemotherapy alone prior to surgery, in patients with resectable stage II–IIIB N2 EGFR mutation-positive NSCLC. Wanting to help patients understand the study, the authors have published a plain language summary alongside the article.
Read the article for free here.
